Summary of patient disposition and dose reductions/discontinuations related to pomalidomide treatment
| . | Pomalidomide dose levels . | ||||
|---|---|---|---|---|---|
| n (%) . | 2 mg (n = 6) . | 3 mg (n = 8) . | 4 mg (n = 14) . | 5 mg (n = 10) . | Total (N = 38) . |
| Patients active in the study* | 0 | 0 | 2 (14) | 2 (20) | 4 (11) |
| Patients withdrawn from the study | 6 (100) | 8 (100) | 12 (86) | 8 (80) | 34 (89) |
| Dose reductions and discontinuations | |||||
| POM dose reduction | 0 | 1 (13) | 3 (21) | 10 (100) | 14 (37) |
| Discontinuation | 6 (100) | 8 (100) | 12 (86) | 8 (80) | 34 (89) |
| Disease progression | 2 (33) | 3 (38) | 5 (36) | 4 (40) | 14 (37) |
| AEs§ | 1 (17) | 0 | 2 (14) | 1 (10) | 4 (11) |
| Withdrawn consent | 1 (17) | 1 (13) | 2 (14) | 2 (20) | 6 (16) |
| Death | 0 | 1 (13) | 2 (14) | 0 | 3 (8) |
| . | Pomalidomide dose levels . | ||||
|---|---|---|---|---|---|
| n (%) . | 2 mg (n = 6) . | 3 mg (n = 8) . | 4 mg (n = 14) . | 5 mg (n = 10) . | Total (N = 38) . |
| Patients active in the study* | 0 | 0 | 2 (14) | 2 (20) | 4 (11) |
| Patients withdrawn from the study | 6 (100) | 8 (100) | 12 (86) | 8 (80) | 34 (89) |
| Dose reductions and discontinuations | |||||
| POM dose reduction | 0 | 1 (13) | 3 (21) | 10 (100) | 14 (37) |
| Discontinuation | 6 (100) | 8 (100) | 12 (86) | 8 (80) | 34 (89) |
| Disease progression | 2 (33) | 3 (38) | 5 (36) | 4 (40) | 14 (37) |
| AEs§ | 1 (17) | 0 | 2 (14) | 1 (10) | 4 (11) |
| Withdrawn consent | 1 (17) | 1 (13) | 2 (14) | 2 (20) | 6 (16) |
| Death | 0 | 1 (13) | 2 (14) | 0 | 3 (8) |